<DOC>
	<DOC>NCT01769196</DOC>
	<brief_summary>This study is to evaluate the efficacy and safety of simtuzumab (GS-6624) in adults with idiopathic pulmonary fibrosis.</brief_summary>
	<brief_title>A Phase 2 Study to See if Simtuzumab (GS-6624) is Safe and Works in Idiopathic Pulmonary Fibrosis (IPF)</brief_title>
	<detailed_description />
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Pulmonary Fibrosis</mesh_term>
	<mesh_term>Idiopathic Pulmonary Fibrosis</mesh_term>
	<mesh_term>Idiopathic Interstitial Pneumonias</mesh_term>
	<criteria>Male or female subjects from 45 to 85 years of age Definite IPF within 3 years prior to screening Be able to walk at least 50 meters Significant diseases other than IPF Obstructive lung disease Aortic aneurysm greater than or equal to 3.5 cm in diameter Treatment with immunosuppressive, cytotoxic, or antifibrotic drugs &lt; 28 days prior to randomization are not permitted. Nacetylcysteine is permitted provided the individual has been on a stable dose for &gt; 4 weeks prior to screening Concomitant use of pirfenidone or nintedanib must be in accordance with the approved prescribing instructions in the country where the site is located Individuals actively listed for lung transplant are excluded. However individuals at transplant centers with long waiting times (greater than 1 year) may be permitted to enter the study after discussion with Medical Monitor.</criteria>
	<gender>All</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>Idiopathic</keyword>
	<keyword>Pulmonary</keyword>
	<keyword>Fibrosis</keyword>
	<keyword>IPF</keyword>
</DOC>